Navigation Links
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis

Drug Effectively Treated 41 to 50% of Patients and Was Well-Tolerated
PRINCETON, NJ, Jun 14, 2007 (MARKET WIRE via COMTEX News Network) -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced results from its completed Phase 2/3 study of liarozole in lamellar ichthyosis, a rare genetic disorder (incidence of approximately 1 in 200,000) which is characterized by a thick scaling of the skin over large body areas. Study results showed liarozole, dosed at 75 mg and 150 mg per day for 12 weeks, was well-tolerated and "effectively treated" the disorder in 41% and 50% of the patients, respectively. The primary efficacy endpoint, "effectively treated," was defined as the percentage of patients that obtained at least a 2 point reduction in investigator's global assessment (IGA) score as defined on a 5 point scale.

The randomized, double-blind, placebo-controlled dose ranging study enrolled 64 patients in three treatment groups. Patients received placebo, 75 mg or 150 mg of liarozole daily for 12 weeks, randomized 1:3:3, respectively. Response rates for the primary endpoint were 41% (11 of 27 patients) for the 75 mg dose, 50% (14 of 28 patients) for the 150 mg dose and 11% (1 of 9 patients) for placebo. The p-values for the 75 and 150 mg per day groups compared to placebo were p=0.2193 and p=0.0557, respectively.

For the secondary endpoints of mean IGA score at week 8 and the overall scaling score at weeks 8 and 12, both liarozole groups achieved statistically significant differences from placebo (p < 0.05). The mean IGA score at week 8 was reduced by 36% and 43% for the 75 and 150 mg liarozole treatment groups, respectively versus 3% for placebo. The mean IGA score for the two liarozole treatment groups continued to improve through 12 weeks. The mean reduction in overall scaling was approximately 45% for both liarozole treatment
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:3/3/2015)... NEW YORK , March 3, 2015  This industry report package ... and future outlook for safety glass in the world and in the ... the package includes country reports from the following countries: ... , Germany , Italy , ... Turkey , United Kingdom , United ...
(Date:3/3/2015)... , March 3, 2015 ... 356 and 240 patients respectively Publications in ... Journal of Clinical Gastroenterology highlight diagnostic value of ... China and across ... Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the ...
(Date:3/3/2015)... Konica Minolta Medical Imaging and Shimadzu Medical ... new, integrated portable X-ray solution, the MobileArt Evolution EFX ... a larger integrated console, and a 17" touch screen ... viewing area to simplify operation and enhance clinical confidence. ... and storage, along with a detector slot that facilitates ...
Breaking Medicine Technology:Global Safety Glass Market to 2019 - Market Size, Top 10 Countries, Trends, and Forecasts 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4Konica Minolta Medical Imaging and Shimadzu Medical Systems USA Introduce MobileArt Evolution EFX AeroDR-i with 17" Touch Monitor to Simplify Operation 2Konica Minolta Medical Imaging and Shimadzu Medical Systems USA Introduce MobileArt Evolution EFX AeroDR-i with 17" Touch Monitor to Simplify Operation 3
... Oct. 20, 2011 Treating patients with the new ... in significantly higher per patient costs and higher net ... by pharmacy benefit manager Prime Therapeutics (Prime).The study will ... Pharmacy,s Educational Conference in Atlanta, Ga. Dabigatran ...
... today announced publication of a peer-reviewed paper that examines ... for removal of varicose veins in a clinical office ... Powered Phlebectomy in an Office Setting:  Procedural Considerations and ... M.D., FACS (AmeriVein Systems, Aurora, Illinois) and published in ...
Cached Medicine Technology:Study Finds New Blood Thinning Medication, Pradaxa®, Comes at High Cost 2InaVein, LLC Announces First Peer-reviewed Publication of TRIVEX® Used In-Office 2
(Date:3/4/2015)... D.C. (PRWEB) March 04, 2015 From ... Professionals (IAPP) Global Privacy Summit 2015 , AvePoint, ... platforms and devices, today introduced the AvePoint Risk ... the complete lifecycle of risk across the enterprise. , ... AvePoint Privacy Impact Assessment (APIA) system – ...
(Date:3/4/2015)... Chicago (PRWEB) March 04, 2015 Professionals ... want more targeted outreach from companies, according to a ... December 2014 survey of 235 professionals with disabilities ... more online job search tools, including ones that are ... meaningful work. Some highlights:, ,     Online job ...
(Date:3/4/2015)... March 04, 2015 Parkview Regional ... that Alan Daugherty has been named chief executive ... has served as interim CEO of Parkview Regional ... has provided tremendous leadership during his tenure as ... hospital strategy and developing relationships with physicians, patients ...
(Date:3/3/2015)... MED-Ed Facilities Boston , the ... for New England, April 7+8, 2015 at the ... related workshops. Sessions offer LUs and several have ... Curtain Walls for Labs and Medical Facilities, Curtain ... facilities are often required to meet more demanding ...
(Date:3/3/2015)... On February 24, 2015, a Toledo, Ohio homeowner ... Court for the Northern District of Ohio against mortgage ... companies Balboa, QBE, and Newport Management. (See Amended Complaint ... The Plaintiff, a Ms. Dolores Gorsuch, says her mortgage ... buy too much insurance at rates that were too ...
Breaking Medicine News(10 mins):Health News:AvePoint Unveils New Solution to Address the Complete Risk Lifecycle at IAPP Global Privacy Summit 2015 2Health News:AvePoint Unveils New Solution to Address the Complete Risk Lifecycle at IAPP Global Privacy Summit 2015 3Health News:AvePoint Unveils New Solution to Address the Complete Risk Lifecycle at IAPP Global Privacy Summit 2015 4Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 2Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 3Health News:Alan Daugherty Named CEO of Parkview Regional Hospital and Ennis Regional Medical Center 2Health News:Alan Daugherty Named CEO of Parkview Regional Hospital and Ennis Regional Medical Center 3Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 2Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 3Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 4Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 5Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 6Health News:Borrower Accuses Mortgage Lenders of Racketeering in Forcing Insurance on Homeowners 2
... will issue a new 16-page report on FRAX to ... report is available at http://www.iofbonehealth.org/publications/frax.html ... free online tool developed by the World Health Organization ... better identify women and men in need of intervention ...
... (DKC) is an autosomal dominant disease that leads to abnormalities ... nails, bone marrow, lungs and gut. Patients with DKC experience ... fatal infections and cancer. Many die before the age of ... to treat its symptoms. At the heart of DKC is ...
... Study led by St. Jude Children,s Research Hospital ... with Down syndrome, fueling hope for new treatment ... new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that ... give rise to cancer. This latest anomaly is particularly ...
... and relaxation exercises can help cut the pain, experts say , ... run away from an injection, so it,s no surprise that children ... it,s time for flu shots this year. , "The good ... to positively impact their child,s experience when getting a needlestick -- ...
... likely the pain, says research led by an 11-year-old, , SATURDAY, ... more than an hour a day increase their chances of having ... lead author of the study knows this all too well. Deniz ... pain among his classmates at Rossman Elementary in St. Louis, Mo., ...
... TSX: COM, , VANCOUVER, Oct. 16 /PRNewswire-FirstCall/ ... ("Cardiome" or the "Company") announced the final results of its modified ... million of its common shares (the "Offer"), which expired at 5:00 ... of its common shares for purchase and cancellation at a purchase ...
Cached Medicine News:Health News:New IOF report explains importance of FRAX in osteoporosis management 2Health News:Mice regain ability to extend telomeres suggesting potential for dyskeratosis congenita therapy 2Health News:New Chromosomal Abnormality Identified in Leukemia Associated with Down Syndrome 2Health News:New Chromosomal Abnormality Identified in Leukemia Associated with Down Syndrome 3Health News:New Chromosomal Abnormality Identified in Leukemia Associated with Down Syndrome 4Health News:Video Games Can Play Havoc With Kids' Joints 2Health News:Video Games Can Play Havoc With Kids' Joints 3Health News:Cardiome Pharma Corp. Announces Final Results of Tender Offer 2Health News:Cardiome Pharma Corp. Announces Final Results of Tender Offer 3Health News:Cardiome Pharma Corp. Announces Final Results of Tender Offer 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: